Scarlet red | CAS#85-83-6 | anticancer drug

MedKoo Cat#: 592699 | Name: Scarlet red

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Scarlet red, also known as Sudan IV, is used in the treatment of split thickness skin graft donor sites and is an anticancer drug. Scarlet red is a lysochrome diazo dye used for the staining of lipids, triglycerides and lipoproteins on frozen paraffin sections.

Chemical Structure

Scarlet red

CAS#85-83-6

Theoretical Analysis

MedKoo Cat#: 592699

Name: Scarlet red

CAS#: 85-83-6

Chemical Formula: C24H20N4O

Exact Mass: 380.1637

Molecular Weight: 380.45

Elemental Analysis: C, 75.77; H, 5.30; N, 14.73; O, 4.21

Price and Availability

Size	Price	Availability	Quantity
5g	USD 250.00	2 Weeks
25g	USD 450.00	2 Weeks

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

Scarlet red; NSC 10472; NSC-10472; NSC10472; Sudan IV; Biebrich scarlet R fat soluble, Fat Ponceau R or 4, Lipid Crimson, Oil Red IV, Scarlet Red Scharlach, Solvent Red 24, Sudan R or BB

IUPAC/Chemical Name

2-Naphthol, 1-(4-o-tolylazo-o-tolylazo)-

InChi Key

RCTGMCJBQGBLKT-PAMTUDGESA-N

InChi Code

InChI=1S/C24H20N4O/c1-16-7-3-6-10-21(16)26-25-19-12-13-22(17(2)15-19)27-28-24-20-9-5-4-8-18(20)11-14-23(24)29/h3-15,29H,1-2H3/b26-25+,28-27+

SMILES Code

OC1=CC=C2C=CC=CC2=C1/N=N/C3=CC=C(/N=N/C4=CC=CC=C4C)C=C3C

Appearance

Solid powder

Purity

>95% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.03.00

More Info

Product Data

Product Data

Instruction

View handling instruction

Biological target:

Scarlet red is a dye.

In vitro activity:

Sudan I, III and IV could affect cell cycle and advanced its differentiation and proliferation. In HepG-2 cells, different doses of Sudan I, III, and IV resulted in a significant change in the DNA/RNA ratio, particularly in the low-dose group. These compounds accelerated the cell cycle from G1 phase to S and G2 phases in SGC-7901 cells, causing changes in DNA content across different cell cycle phases. Reference: Huan Jing Ke Xue. 2006 Jun;27(6):1201-7. https://pubmed.ncbi.nlm.nih.gov/16921962/

In vivo activity:

Scarlet red was shown to be significantly better than Kaltostat in the healing of split thickness skin graft donor sites. Forty-six patients had split thickness skin grafts harvested from the upper inner thigh. 72% of wounds dressed with Kaltostat and 84% of wounds dressed with scarlet red were healed at 10 days. Reference: Br J Plast Surg. 1991 May-Jun;44(4):247-9. https://pubmed.ncbi.nlm.nih.gov/2059780/

	Solvent	mg/mL	mM
Solubility
	DMSO	5.0	13.14

Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 380.45 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

Formulation protocol:

1. Ji YB, Ji CF, Gao SY, Lang L, Yu L. [Effect of Sudan I, III and IV on proliferation of HepG-2 and SGC-7901]. Huan Jing Ke Xue. 2006 Jun;27(6):1201-7. Chinese. PMID: 16921962. 2. Refat NA, Ibrahim ZS, Moustafa GG, Sakamoto KQ, Ishizuka M, Fujita S. The induction of cytochrome P450 1A1 by sudan dyes. J Biochem Mol Toxicol. 2008 Mar-Apr;22(2):77-84. doi: 10.1002/jbt.20220. PMID: 18418879. 3. Lawrence JE, Blake GB. A comparison of calcium alginate and scarlet red dressings in the healing of split thickness skin graft donor sites. Br J Plast Surg. 1991 May-Jun;44(4):247-9. doi: 10.1016/0007-1226(91)90065-r. PMID: 2059780.

In vitro protocol:

1. Ji YB, Ji CF, Gao SY, Lang L, Yu L. [Effect of Sudan I, III and IV on proliferation of HepG-2 and SGC-7901]. Huan Jing Ke Xue. 2006 Jun;27(6):1201-7. Chinese. PMID: 16921962.

In vivo protocol:

1. Refat NA, Ibrahim ZS, Moustafa GG, Sakamoto KQ, Ishizuka M, Fujita S. The induction of cytochrome P450 1A1 by sudan dyes. J Biochem Mol Toxicol. 2008 Mar-Apr;22(2):77-84. doi: 10.1002/jbt.20220. PMID: 18418879. 2. Lawrence JE, Blake GB. A comparison of calcium alginate and scarlet red dressings in the healing of split thickness skin graft donor sites. Br J Plast Surg. 1991 May-Jun;44(4):247-9. doi: 10.1016/0007-1226(91)90065-r. PMID: 2059780.

1: VASILIEV JM, CHEUNG AB. Evolution of epithelial proliferation induced by scarlet red in the skin of normal and carcinogen-treated rabbits. Br J Cancer. 1962 Jun;16:238-45. PubMed PMID: 13925015; PubMed Central PMCID: PMC2070933. 2: MOEGEN P. [A comparison of chlorophyll fluorescence and scarlet red staining in fat determination]. Zentralbl Allg Pathol. 1951 Nov 22;88(1-2):21-3. Undetermined Language. PubMed PMID: 14914075. 3: Hugill JV. Acceleration of healing of skin graft donor sites using scarlet red ointment. Am Surg. 1978 Jun;44(6):352-4. PubMed PMID: 354448. 4: Prasad JK, Feller I, Thomson PD. A prospective controlled trial of Biobrane versus scarlet red on skin graft donor areas. J Burn Care Rehabil. 1987 Sep-Oct;8(5):384-6. PubMed PMID: 3312216. 5: Tan ST, Roberts RH, Blake GB. Comparing DuoDERM E with scarlet red in the treatment of split skin graft donor sites. Br J Plast Surg. 1993 Jan;46(1):79-81. PubMed PMID: 8431748. 6: McEVITT WG. Marked sensitivity to scarlet red ointment; loss of skin grafts and destruction of donor areas. Plast Reconstr Surg (1946). 1946 Sep;1:193-5. PubMed PMID: 21000876. 7: UMEDA M. Production of rat sarcoma by injections of tween 80 solution of scarlet red. Gan. 1958 Mar;49(1):27-31. PubMed PMID: 13548293. 8: UMEDA M. [Production of rat sarcoma by injections of tween 80 solution of scarlet red]. Gan. 1957 Dec;48(4):579-80. Japanese. PubMed PMID: 13524514. 9: Lawrence JE, Blake GB. A comparison of calcium alginate and scarlet red dressings in the healing of split thickness skin graft donor sites. Br J Plast Surg. 1991 May-Jun;44(4):247-9. PubMed PMID: 2059780. 10: Morris WT, Lamb AM. Painless split skin donor sites: a controlled double-blind trial of Opsite, scarlet red and bupivacaine. Aust N Z J Surg. 1990 Aug;60(8):617-20. PubMed PMID: 2202283. 11: UNGER M. A different treatment of chronic purulent otitis media; deep lavage, aeration and application of gold foil membrane bearing ointment of scarlet red. Arch Otolaryngol. 1947 Nov;46(5):670-80. PubMed PMID: 18896820.